Connect your AI

Disc Medicine IRON Stock-Based Comp

Stock-Based Comp at other companies

Bristol-Myers SquibbBMY

$146M+1.4%

Vertex PharmaceuticalsVRTX

$166.4M+0.2%

Protagonist TherapeuticsPTGX

$14.52M+5.2%

Agios PharmaceuticalsAGIO

$15.54M+36.8%

Beam TherapeuticsBEAM

$19.04M-28.6%

Travere Therapeutics, Inc.TVTX

$16.15M+40.5%

Segments

By segment

Significant Segment Expense Category$11.95M+87.7%

Other financials

Income statement

Operating income-$69.5M-74.0%

Net income-$63.5M-86.3%

EPS (diluted)-$1.65-61.8%

Balance sheet

Cash & equivalents$88.9M-27.5%

Total debt$31.1M+1.4%

Total equity$688.4M+4.3%

Total assets$750.2M+5.8%

Cash flow

Operating cash flow-$62.2M-50.4%

CapEx--100%

Free cash flow-$62.2M-47.4%

Valuation

Market cap$2.69B+42.2%

Enterprise value$2.63B+46.7%

Returns & leverage

Return on equity-35.8%+41.3pp

Debt / equity0×0.0×

Current ratio24×-13.6×

Where this comes from

Reported directly by Disc Medicine in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Disc Medicine’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Disc Medicine's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Disc Medicine's stock-based comp?: Disc Medicine (IRON) reported stock-based comp of $11.95M in Q1 2026.
How has Disc Medicine's stock-based comp changed year-over-year?: Disc Medicine's stock-based comp increased by 87.7% year-over-year, from $6.36M to $11.95M.
What is the long-term trend for Disc Medicine's stock-based comp?: Over 3 years (2022 to 2025), Disc Medicine's stock-based comp has grown at a 154.3% compound annual growth rate (CAGR), from $2.09M to $34.34M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.